Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172140 | 0.86 | MAOB (0.76) | MAOBNR4A2IDO1MAPTPOLB | |
| SCHEMBL4640143 | 0.86 | MAOB (0.76) | MAOBNR4A2IDO1MAPTPOLB | |
| SCHEMBL5669711 | 0.85 | MAOB (0.74) | MAOBNR4A2FFAR1FFAR4IDO1 | |
| SCHEMBL5087361 | 0.85 | MAOB (0.74) | MAOBNR4A2FFAR1FFAR4IDO1 | |
| SCHEMBL23350560 | 0.84 | MAOB (0.73) | MAOBNR4A2FFAR1FFAR4IDO1 | |
| SCHEMBL23266152 | 0.83 | MAOB (0.71) | MAOBNR4A2FFAR1FFAR4IDO1 | |
| SCHEMBL13258589 | 0.82 | MAOB (0.70) | MAOBNR4A2FFAR1FFAR4IDO1 | |
| SCHEMBL11214112 | 0.81 | MAOB (0.71) | MAOBNR4A2FFAR1FFAR4IDO1 | |
| SCHEMBL11214114 | 0.81 | MAOB (0.71) | MAOBNR4A2FFAR1FFAR4IDO1 | |
| SCHEMBL3321627 | 0.81 | MAOB (0.68) | MAOBNR4A2FFAR1FFAR4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9199973-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912205-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-21 | — | — | US | disclosed |
| US-8513262-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20070238875-A1 | HETEROCYCLIC COMPOUNDS | LEO OSPREY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070015775-A1 | HETEROCYCLIC COMPOUNDS | LEO OSPREY LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| US-20050130996-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2005-06-16 | — | — | US | disclosed |
| EP-1454907-A1 | Quninazoline and pyridopyrmidine derivatives | Glaxo Group Limited (GB) | 2004-09-08 | — | — | EP | disclosed |
| US-6727256-B1 | 4-AMINOQUINAZOLINE DERIVATIVES AS ANTICARCINOGENIC AGENTS | SMITHKLINE BEECHAM CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6713485-B2 | ANTIPROLIFERATIVE AGENTS; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM CORPORATION | 2004-03-30 | — | — | US | disclosed |
| CN-1134438-C | Bicyclic heteroaromatic compounds, preparation method and use thereof | �ձ���ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | LEO OSPREY LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| CN-1292788-A | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 2001-04-25 | — | — | CN | disclosed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | CCNH, HRH2, HRH1 | MAOB 110/4885NR4A2 2112/4885FFAR1 3051/4885 |
| US-20020147205-A1 | Heterocyclic compounds | ERBB2, ERBB3, ERBB4 | MAOB 945/4885NR4A2 1266/4885FFAR1 4068/4885 |
| US-20050130996-A1 | Heterocyclic compounds | CCNH, SDHA, CYP1A2 | MAOB 32/4885NR4A2 1181/4885FFAR1 3708/4885 |
| US-20070015775-A1 | HETEROCYCLIC COMPOUNDS | CCNH, SDHA, CYP1A2 | MAOB 32/4885NR4A2 1181/4885FFAR1 3708/4885 |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885NR4A2 2398/4885FFAR1 2256/4885 |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ABL1, ERBB2, CDK2 | MAOB 327/4885NR4A2 1824/4885FFAR1 2635/4885 |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | ABL1, ERBB2, SRC | MAOB 617/4885NR4A2 2398/4885FFAR1 2256/4885 |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885NR4A2 2398/4885FFAR1 2256/4885 |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885NR4A2 2398/4885FFAR1 2256/4885 |
| US-20070238875-A1 | HETEROCYCLIC COMPOUNDS | CCNH, SDHA, CYP1A2 | MAOB 32/4885NR4A2 1181/4885FFAR1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.